Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Eosinophils are pro-inflammatory cells that make a major contribution to allergic diseases affecting the upper and lower airways, skin and gastrointestinal tract. IL-5 is central to eosinophil maturation and release from the bone marrow, and to the subsequent accumulation, activation and persistence of eosinophils in the tissues. Reslizumab from Ception Therapeutics Inc is a humanized mAb with potent IL-5-neutralizing effects. The agent inhibited eosinophilia in several animal models; reductions in airway hyperactivity and bronchoconstriction were also observed. Clinical trials for reslizumab have been completed in a small number of patients with asthma, nasal polyposis, hypereosinophilic syndrome (HES) and eosinophil gastroenteritis (EG). Eosinophil depletion was observed in all trials, but clinical responses were often limited, particularly in patients with asthma; furthermore, some patients exhibited rebound of disease to levels greater than baseline. At the time of publication, phase II/III and phase III trials were ongoing in patients with eosinophilic esophagitis (EE), and a phase II trial was ongoing in patients with asthma. Reslizumab is a potentially efficacious and well-tolerated treatment for EG, EE, HES and eosinophilic polyposis, although more trials are required to understand the underlying mechanism of disease rebound. However, the rarity of conditions such as HES, EE and EG makes the conduct of such trials difficult.
Original languageEnglish
Pages (from-to)329-336
Number of pages8
JournalCurrent Opinion in Molecular Therapeutics
Volume11
Issue number3
Publication statusPublished - Jun 2009

Fingerprint

Interleukin-5
Eosinophils
Eosinophilic Esophagitis
Hypereosinophilic Syndrome
Gastroenteritis
Asthma
Therapeutics
Clinical Trials
Bronchoconstriction
Eosinophilia
reslizumab
Nose
Publications
Gastrointestinal Tract
Animal Models
Bone Marrow
Skin

Keywords

  • animals
  • antibodies, monoclonal
  • clinical trials as topic
  • drug evaluation, preclinical
  • eosinophils
  • humans
  • inflammation
  • interleukin-5
  • patents as topic
  • structure-activity relationship

Cite this

@article{bede880db2f44ee286458f52a0617a4b,
title = "Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions",
abstract = "Eosinophils are pro-inflammatory cells that make a major contribution to allergic diseases affecting the upper and lower airways, skin and gastrointestinal tract. IL-5 is central to eosinophil maturation and release from the bone marrow, and to the subsequent accumulation, activation and persistence of eosinophils in the tissues. Reslizumab from Ception Therapeutics Inc is a humanized mAb with potent IL-5-neutralizing effects. The agent inhibited eosinophilia in several animal models; reductions in airway hyperactivity and bronchoconstriction were also observed. Clinical trials for reslizumab have been completed in a small number of patients with asthma, nasal polyposis, hypereosinophilic syndrome (HES) and eosinophil gastroenteritis (EG). Eosinophil depletion was observed in all trials, but clinical responses were often limited, particularly in patients with asthma; furthermore, some patients exhibited rebound of disease to levels greater than baseline. At the time of publication, phase II/III and phase III trials were ongoing in patients with eosinophilic esophagitis (EE), and a phase II trial was ongoing in patients with asthma. Reslizumab is a potentially efficacious and well-tolerated treatment for EG, EE, HES and eosinophilic polyposis, although more trials are required to understand the underlying mechanism of disease rebound. However, the rarity of conditions such as HES, EE and EG makes the conduct of such trials difficult.",
keywords = "animals, antibodies, monoclonal, clinical trials as topic, drug evaluation, preclinical, eosinophils, humans, inflammation, interleukin-5, patents as topic, structure-activity relationship",
author = "Walsh, {Garry M}",
year = "2009",
month = "6",
language = "English",
volume = "11",
pages = "329--336",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "3",

}

TY - JOUR

T1 - Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions

AU - Walsh, Garry M

PY - 2009/6

Y1 - 2009/6

N2 - Eosinophils are pro-inflammatory cells that make a major contribution to allergic diseases affecting the upper and lower airways, skin and gastrointestinal tract. IL-5 is central to eosinophil maturation and release from the bone marrow, and to the subsequent accumulation, activation and persistence of eosinophils in the tissues. Reslizumab from Ception Therapeutics Inc is a humanized mAb with potent IL-5-neutralizing effects. The agent inhibited eosinophilia in several animal models; reductions in airway hyperactivity and bronchoconstriction were also observed. Clinical trials for reslizumab have been completed in a small number of patients with asthma, nasal polyposis, hypereosinophilic syndrome (HES) and eosinophil gastroenteritis (EG). Eosinophil depletion was observed in all trials, but clinical responses were often limited, particularly in patients with asthma; furthermore, some patients exhibited rebound of disease to levels greater than baseline. At the time of publication, phase II/III and phase III trials were ongoing in patients with eosinophilic esophagitis (EE), and a phase II trial was ongoing in patients with asthma. Reslizumab is a potentially efficacious and well-tolerated treatment for EG, EE, HES and eosinophilic polyposis, although more trials are required to understand the underlying mechanism of disease rebound. However, the rarity of conditions such as HES, EE and EG makes the conduct of such trials difficult.

AB - Eosinophils are pro-inflammatory cells that make a major contribution to allergic diseases affecting the upper and lower airways, skin and gastrointestinal tract. IL-5 is central to eosinophil maturation and release from the bone marrow, and to the subsequent accumulation, activation and persistence of eosinophils in the tissues. Reslizumab from Ception Therapeutics Inc is a humanized mAb with potent IL-5-neutralizing effects. The agent inhibited eosinophilia in several animal models; reductions in airway hyperactivity and bronchoconstriction were also observed. Clinical trials for reslizumab have been completed in a small number of patients with asthma, nasal polyposis, hypereosinophilic syndrome (HES) and eosinophil gastroenteritis (EG). Eosinophil depletion was observed in all trials, but clinical responses were often limited, particularly in patients with asthma; furthermore, some patients exhibited rebound of disease to levels greater than baseline. At the time of publication, phase II/III and phase III trials were ongoing in patients with eosinophilic esophagitis (EE), and a phase II trial was ongoing in patients with asthma. Reslizumab is a potentially efficacious and well-tolerated treatment for EG, EE, HES and eosinophilic polyposis, although more trials are required to understand the underlying mechanism of disease rebound. However, the rarity of conditions such as HES, EE and EG makes the conduct of such trials difficult.

KW - animals

KW - antibodies, monoclonal

KW - clinical trials as topic

KW - drug evaluation, preclinical

KW - eosinophils

KW - humans

KW - inflammation

KW - interleukin-5

KW - patents as topic

KW - structure-activity relationship

M3 - Article

VL - 11

SP - 329

EP - 336

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 3

ER -